Third
FDA Delays Approval of Zealand Pharma’s Dasiglucagon for Congenital Hyperinsulinism Due to Third-Party Manufacturing Issues
Zealand Pharma, dasiglucagon, congenital hyperinsulinism, FDA, Complete Response Letter, third-party manufacturing issues
Third Arc Bio Debuts with $165M Funding and Former J&J Executives at the Helm
Third Arc Bio, J&J, biotech, funding, executives, cancer, immune disease